XML 51 R36.htm IDEA: XBRL DOCUMENT
v3.25.1

REVENUES - Summary of Total Revenues (Details) - USD ($) $ in Millions | 3 Months Ended
--- | ---
Mar. 31, 2025 | Mar. 31, 2024
Disaggregation of Revenue [Line Items] |  |
Total revenues | $ 6,667 | $ 6,686
U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 4,668 | 4,633
Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 1,084 | 1,159
Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 915 | 894
Total product sales |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 6,613 | 6,647
Total product sales | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 4,631 | 4,609
Total product sales | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 1,073 | 1,144
Total product sales | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 909 | 894
Total HIV |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 4,587 | 4,342
Total HIV | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 3,664 | 3,405
Total HIV | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 553 | 596
Total HIV | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 370 | 342
Biktarvy |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 3,150 | 2,946
Biktarvy | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 2,474 | 2,315
Biktarvy | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 375 | 365
Biktarvy | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 301 | 265
Descovy |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 586 | 426
Descovy | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 538 | 371
Descovy | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 21 | 26
Descovy | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 27 | 29
Genvoya |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 364 | 403
Genvoya | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 305 | 332
Genvoya | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 40 | 49
Genvoya | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 19 | 21
Odefsey |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 281 | 310
Odefsey | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 215 | 223
Odefsey | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 57 | 76
Odefsey | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 10 | 11
Symtuza - Revenue share |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 114 | 141
Symtuza - Revenue share | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 82 | 104
Symtuza - Revenue share | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 29 | 33
Symtuza - Revenue share | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 3 | 3
Other HIV |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 91 | 117
Other HIV | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 50 | 60
Other HIV | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 31 | 45
Other HIV | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 10 | 12
Total Liver Disease |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 758 | 737
Total Liver Disease | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 335 | 385
Total Liver Disease | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 168 | 137
Total Liver Disease | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 256 | 215
Sofosbuvir/Velpatasvir |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 346 | 405
Sofosbuvir/Velpatasvir | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 166 | 248
Sofosbuvir/Velpatasvir | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 80 | 79
Sofosbuvir/Velpatasvir | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 99 | 78
Vemlidy |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 252 | 225
Vemlidy | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 100 | 95
Vemlidy | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 12 | 11
Vemlidy | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 140 | 119
Other Liver Disease |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 161 | 107
Other Liver Disease | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 68 | 42
Other Liver Disease | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 76 | 47
Other Liver Disease | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 17 | 19
Veklury |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 302 | 555
Veklury | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 199 | 315
Veklury | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 22 | 70
Veklury | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 82 | 169
Total Oncology |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 757 | 789
Total Oncology | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 381 | 431
Total Oncology | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 255 | 262
Total Oncology | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 121 | 96
Total Cell Therapy |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 464 | 480
Total Cell Therapy | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 200 | 225
Total Cell Therapy | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 180 | 195
Total Cell Therapy | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 84 | 60
Tecartus |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 78 | 100
Tecartus | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 40 | 55
Tecartus | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 31 | 36
Tecartus | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 8 | 8
Yescarta |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 386 | 380
Yescarta | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 160 | 170
Yescarta | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 149 | 158
Yescarta | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 77 | 52
Trodelvy |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 293 | 309
Trodelvy | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 181 | 206
Trodelvy | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 75 | 68
Trodelvy | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 37 | 36
Total Other |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 209 | 224
Total Other | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 52 | 73
Total Other | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 76 | 79
Total Other | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 81 | 71
AmBisome |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 139 | 144
AmBisome | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 5 | 14
AmBisome | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 67 | 70
AmBisome | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 66 | 60
Other |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 70 | 80
Other | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 47 | 59
Other | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 9 | 9
Other | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 14 | 12
Royalty, contract and other revenues |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 54 | 39
Royalty, contract and other revenues | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 37 | 23
Royalty, contract and other revenues | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 11 | 15
Royalty, contract and other revenues | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | $ 6 | $ 1

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=gild_RestOfWorldMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsSymtuzaRevenueShareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsOtherHIVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_LiverDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_LiverDiseaseProductsSofosbuvirVelpatasvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_LiverDiseaseProductsVemlidyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_LiverDiseaseProductsOtherLiverDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_VekluryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OncologyProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_TrodelvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |